<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1408222482
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2007
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        DIOVAN 320MG F.C. TABLETS
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        VALSARTAN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        320
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        54.85
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Siegfried Barbera, S.L" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Siegfried Barbera, S.L
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 439]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Novartis Saudi Limited
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            NOVARTIS
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C09CA03
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Diovan is</strong></p><p>Diovan belongs to a class of medicines known as angiotensin-II receptor antagonists, which help to control high blood pressure.</p><p><strong>What Diovan is used for</strong></p><p>Diovan is used to treat high blood pressure in adults and in children and adolescents 6-18 years of age. High blood pressure increases the workload of the heart and arteries. If it continues for a long time, it can damage the blood vessels of the brain, heart, and kidneys, and may result in a stroke, heart failure, or kidney failure. High blood pressure increases the risk of heart attacks. Lowering your blood pressure to normal reduces the risk of developing these disorders.</p><p>Diovan is used to treat adult heart failure patients. Heart failure is associated with shortness of breath, and swelling of the feet and legs due to fluid build-up. Heart failure means that the heart muscle cannot pump blood strongly enough to supply all the blood needed throughout the body.</p><p>Diovan can also be used to treat adults after a heart attack (myocardial infarction) to improve survival and reduce further heart problems.</p><p>Diovan is also used to delay the progression to diabetes in adults with high blood pressure and above normal blood sugar levels when combined with lifestyle modifications as recommended by your doctor.</p><p><strong>How Diovan works</strong></p><p>Angiotensin II is a natural substance in the body that causes blood vessels to tighten, thus causing your blood pressure to increase. Diovan works by blocking the effect of angiotensin II. As a result, blood vessels relax and blood pressure is lowered.</p><p>If you have any question about how Diovan works or why this medicine has been prescribed for you, ask your doctor.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Follow your doctor&rsquo;s instructions carefully. They may differ from the general instructions contained in this leaflet</p><p>a.&nbsp;&nbsp;&nbsp; Do not take Diovan</p><ul><li>if you are <strong>allergic</strong> (hypersensitive) to valsartan or any of the other ingredients of this medicine (listed in section 6).</li><li>if you have <strong>severe liver disease.</strong></li><li>if you are <strong>more than 3&nbsp;months pregnant </strong>(it is also better to avoid Diovan in early pregnancy - see pregnancy section).</li></ul><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have diabetes or impaired kidney function and you are treated with a blood pressure lowering medicine containing aliskiren</p><p>If either of these apply to you, <strong>tell your doctor and do not take Diovan</strong>.</p><p>b.&nbsp;&nbsp;&nbsp; &nbsp;Take special care with Diovan</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you have </strong>a liver disease</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have a serious kidney disease or are undergoing dialysis</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are suffering from a narrowing of the kidney artery.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have recently undergone kidney transplantation (received a new kidney).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have severe heart disease other than heart failure or heart attack.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have ever experienced swelling of the tongue and face caused by an allergic reaction called angioedema when taking another drug (including ACE inhibitors), tell your doctor. If these symptoms occur when you are taking Diovan, stop taking Diovan immediately and never take it again. See also section 4, &ldquo;Possible side effects&rdquo;.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are taking medicines that increase the amount of potassium in your blood. These include potassium supplements or salt substitutes containing potassium, potassium-sparing medicines and heparin. It may be necessary to check the amount of potassium in your blood at regular intervals.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you suffer from aldosteronism. This is a disease in which your adrenal glands make too much of the hormone aldosterone. If this applies to you, the use of Diovan is not recommended.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have lost a lot of fluid (dehydration) caused by diarrhoea, vomiting, or high doses of water tablets (diuretics).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are taking any of the following medicines used to treat high blood pressure:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; an ACE inhibitor (for example enalapril, lisinopril, ramipril), in particular if you have diabetes-related kidney problems.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; aliskiren</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are being treated with an ACE inhibitor together with certain other medicines to treat your heart failure, which are known as mineralocorticoid receptors antagonists (MRA) (for example spironolactone, eplerenone) or betablockers (for example metoprolol).</p><p>&nbsp;</p><p>Your doctor may check your kidney function, blood pressure, and the amount of electrolytes (e.g. potassium) in your blood at regular intervals.</p><p>See also information under the heading &ldquo;Do not take Diovan&rdquo;</p><p>You must tell your doctor if you think you are <u>(</u><u>or might become</u><u>)</u> pregnant. Diovan is not recommended in early pregnancy, and must not be taken if you are more than 3&nbsp;months pregnant, as it may cause serious harm to your baby if used at that stage (see pregnancy section).</p><p>&nbsp;</p><p><strong>c.&nbsp;&nbsp;&nbsp; </strong><strong>Taking other medicines herbal or dietary supplements</strong></p><p><strong>Tell your doctor or pharmacist </strong>if you are taking or have recently taken any other medicines,</p><p>The effect of the treatment can be influenced if Diovan is taken together with certain other medicines. It may be necessary to change the dose, to take other precautions, or in some cases to stop taking one of the medicines. This applies to both prescription and non-prescription medicines, especially:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>other medicines that lower blood pressure</strong>, especially <strong>water tablets</strong> (diuretics), ACE inhibitors (such as enalapril, lisinopril, etc.,) or aliskiren (see also information under the headings &ldquo;Do not take Diovan&rdquo; and &ldquo;Warnings and precautions&rdquo;).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>medicines that increase the amount of potassium</strong> in your blood. These include potassium supplements or salt substitutes containing potassium, potassium-sparing medicines and heparin.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>certain type of pain killers</strong> called non-steroidal anti-inflammatory medicines <strong>(NSAIDs)</strong>.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; some antibiotics (rifamycin group), a drug used to protect against transplant rejection (ciclosporin) or an antiretroviral drug used to treat HIV/AIDS infection (ritonavir). These drugs may increase the effect of Diovan.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>lithium</strong>, a medicine used to treat some types of psychiatric illness.</p><p>&nbsp;</p><p><strong>In addition:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are being <strong>treated after a heart attack,</strong> a combination with<strong> ACE inhibitors</strong> (a medication to treat heart attack) is not recommended.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are being <strong>treated for heart failure,</strong> a triple combination with<strong> ACE inhibitors and other medicines to treat your heart failure which are known as mineralocorticoid receptors antagonists (MRA) (for example spironolactone, epleronone) or beta blockers</strong> (for example metoprolol) is not recommended<strong>.</strong></p><p>d.&nbsp;&nbsp;&nbsp; Taking Diovan with food and drink</p><p>You can take Diovan with or without food.</p><p>Older people (age 65 and over)</p><p>You can also use Diovan if you are 65&nbsp;years of age or older.</p><p>Children (below the age of 6 years)</p><p>The safety and efficacy of Diovan have not been established in children below the age of 6 years.</p><p>e.&nbsp;&nbsp;&nbsp; Pregnancy and breast-feeding</p><ul><li><strong>You must tell your doctor if you think that you are (<u>or might become</u>) pregnant</strong>. Your doctor will normally advise you to stop taking Diovan before you become pregnant or as soon as you know you are pregnant, and will advise you to take another medicine instead of Diovan. Diovan is not recommended in early pregnancy, and must not be taken when more than 3&nbsp;months pregnant, as it may cause serious harm to your baby if it is used after the third month of pregnancy.</li></ul><ul><li><strong>Tell your doctor if you are breast-feeding or about to start breast-feeding.</strong> Diovan is not recommended for mothers who are breast-feeding, and your doctor may choose another treatment for you if you wish to breast-feed, especially if your baby is newborn, or was born prematurely.</li></ul><p>f.&nbsp;&nbsp;&nbsp;&nbsp; Driving and using machines</p><p>Before you drive a vehicle, use tools or operate machines, or carry out other activities that require concentration, make sure you know how Valsartan affects you. Like many other medicines used to treat high blood pressure, Valsartan may in rare cases cause dizziness and affect the ability to concentrate.&rdquo;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Follow your doctor&rsquo;s instructions carefully. Do not exceed the recommended dose.</p><p>Patients who have high blood pressure often do not notice any signs of this problem. Many may feel quite normal. This makes it all the more important for you to keep your appointments with the doctor even if you are feeling well. It is very important that you take this medicine exactly as your doctor tells you in order to get the best results and reduce the risk of side effects.</p><p>Diovan is for oral use only.</p><p><strong>How much Diovan to take</strong></p><p>Always take this medicine exactly as your doctor has told you in order to get the best results and reduce the risk of side effects. Check with your doctor or pharmacist if you are not sure. People with high blood pressure often do not notice any signs of this problem. Many may feel quite normal. This makes it all the more important for you to keep your appointments with the doctor even if you are feeling well.</p><p>&nbsp;</p><p><strong>Adult patients with high blood pressure: </strong>The recommended dose is 80&nbsp;mg daily. In some cases your doctor may prescribe higher doses (e.g. 160&nbsp;mg or 320&nbsp;mg). He may also combine Diovan with an additional medicine (e.g. a diuretic).</p><p>&nbsp;</p><p><strong>Children and adolescents (6 to 18</strong>&nbsp;<strong>years of age) with high blood pressure:</strong></p><p>In patients who weigh less than 35&nbsp;kg the recommended dose is 40&nbsp;mg of valsartan once daily.</p><p>In patients who weigh 35&nbsp;kg or more the recommended starting dose is 80&nbsp;mg of valsartan once daily.</p><p>In some cases your doctor may prescribe higher doses (the dose can be increased to 160&nbsp;mg and to a maximum of 320&nbsp;mg).</p><p>&nbsp;</p><p><strong>Adult patients after a recent heart attack: </strong>After a heart attack the treatment is generally started as early as after 12&nbsp;hours, usually at a low dose of 20&nbsp;mg twice daily. You obtain the 20&nbsp;mg dose by dividing the 40&nbsp;mg tablet. Your doctor will increase this dose gradually over several weeks to a maximum of 160&nbsp;mg twice daily. The final dose depends on what you as an individual patient can tolerate.</p><p>Diovan can be given together with other treatment for heart attack, and your doctor will decide which treatment is suitable for you.</p><p>&nbsp;</p><p><strong>Adult patients with heart failure:</strong> Treatment starts generally with 40&nbsp;mg twice daily. Your doctor will increase the dose gradually over several weeks to a maximum of 160&nbsp;mg twice daily. The final dose depends on what you as an individual patient can tolerate.</p><p>Diovan can be given together with other treatment for heart failure, and your doctor will decide which treatment is suitable for you.</p><p>You can take Diovan with or without food. Swallow Diovan with a glass of water.</p><p>Take Diovan at about the same time each day.</p><p>a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you take more Diovan than you should</p><p>If you experience severe dizziness and/or fainting, contact your doctor immediately and lie down. If you have accidentally taken too many tablets, contact your doctor, pharmacist, or hospital.</p><p>b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you forget to take Diovan</p><p>If you forget to take a dose, take it as soon as you remember. However, if it is almost time for your next dose, skip the dose you missed.</p><p>. Do not take a double dose to make up for the forgotten dose.</p><p>c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you stop taking Diovan</p><p>Stopping your treatment with Diovan may cause your disease to get worse. Do not stop taking your medicine unless your doctor tells you to.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>&nbsp;<strong>Some side effects can be serious and need immediate medical attention:</strong></p><p>You may experience symptoms of angioedema (a specific allergic reaction), such as</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swollen face, lips, tongue or throat</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty in breathing or swallowing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hives, itching</p><p><strong>If you get any of these symptoms, stop taking Diovan and contact your doctor straight away (see also section 2 &ldquo;Warnings and precautions&rdquo;).</strong></p><p>&nbsp;</p><p><strong>Other side effects include:</strong></p><p>&nbsp;</p><p><em>Common</em><em> (may affect up to 1 in 10 people):</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low blood pressure with or without symptoms such as dizziness and fainting when standing up</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased kidney function (signs of renal impairment)</p><p>&nbsp;</p><p><em>Uncommon</em><em> (may affect up to 1 in 100 people):</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; angioedema (see section &ldquo;Some symptoms need immediate medical attention&rdquo;)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sudden loss of consciousness (syncope)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; spinning sensation (vertigo)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severely decreased kidney function (signs of acute renal failure)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle spasms, abnormal heart rhythm (signs of hyperkalaemia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; breathlessness, difficulty breathing when lying down, swelling of the feet or legs (signs of cardiac failure)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cough</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abdominal pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nausea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tiredness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; weakness</p><p><em>&nbsp;</em></p><p><em>Not known (frequency cannot be estimated from the available data):</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blistering skin (sign of dermatitis bullous)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; allergic reactions with rash, itching and hives; symptoms of fever, swollen joints and joint pain, muscle pain, swollen lymph nodes and/or flu-like symptoms may occur (signs of serum sickness)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; purplish-red spots, fever, itching (signs of inflammation of blood vessels also called vasculitis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; unusual bleeding or bruising (signs of thrombocytopenia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle pain (myalgia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever, sore throat or mouth ulcers due to infections (symptoms of low level of white blood cells also called neutropenia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decrease of level of haemoglobin and decrease of the percentage of red blood cells in the blood (which can lead to anaemia in severe cases)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increase of level of potassium in the blood (which can trigger muscle spasms and abnormal heart rhythm in severe cases)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; elevation of liver function values (which can indicate liver damage) including an increase of bilirubin in the blood (which can trigger yellow skin and eyes in severe cases)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increase of level of blood urea nitrogen and increase of level of serum creatinine (which can indicate abnormal kidney function)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low level of sodium in the blood (which can trigger tiredness, confusion, muscle twitching and/or convulsions in severe cases)</p><p>&nbsp;</p><p>The frequency of some side effects may vary depending on your condition. For example, side effects such as dizziness, and decreased kidney function, were seen less frequently in adult patients treated with high blood pressure than in adult patients treated for heart failure or after a recent heart attack.</p><p>Side effects in children and adolescents are similar to those seen in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep out of the reach and sight of children;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not store above 30&deg;C.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store your tablets in the original package;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use Diovan after the expiry date shown on the pack;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The <strong>active substance</strong> of Diovan is available as film-coated tablets which contain 40 mg, 80&nbsp;mg, 160 mg or 320 mg valsartan.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;The active substance of Diovan is valsartan.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The <strong>other ingredients</strong> of the film coated tablets are microcrystalline cellulose, crospovidone, colloidal anhydrous silica, magnesium stearate, hypromellose, titanium dioxide (E171) Macrogol&nbsp;8000, red iron oxide (E172), yellow iron oxide (E172), black iron oxide (E172) (40&nbsp;mg, 160&nbsp;mg and 320&nbsp;mg), brown iron oxide (mixture of red iron oxide and black iron oxide (320&nbsp;mg only).</p><p>This information might differ in some countries</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Diovan is supplied as film-coated tablets in four strengths:
Diovan 40 mg film-coated tablets are yellow, ovaloid, scored on one side, slightly convex, with beveled edges, debossed on one side with DO and with NVR on the other side. The score line on one side of Diovan 40 mg FCT is to divide the tablet into equal doses.
Diovan 80 mg film-coated tablets are pale red, round, scored on one side, slightly convex, with beveled edges, debossed on one side with D/V and NVR on the other side.
Diovan 160 mg film-coated tablets are grey-orange, ovaloid, scored on one side, convex, debossed on one side with DX/DX and NVR on the other side.
Diovan 320 mg film-coated tablets are dark grey-violet, ovaloid with beveled edges, one side with debossing DXL and NVR on the other side.
The score line on one side of Diovan 80 mg, 160 mg or 320 mg FCT is only to facilitate breaking for ease of swallowing and not to divide into equal dose.
Not all packs might be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The Marketing Authorization Holder for this Product is Novartis Pharma AG.</p><p>www.Novartis.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                by Swedish Medical Products Agency in 03-2018 
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>ما هو عقار ديوفان؟</strong></p><p dir="RTL">ينتمي عقار<strong> </strong>ديوفان إلى فئة من الأدوية تُعرف باسم &quot;مناهضات مستقبلات الأنجيوتنسين 2&quot;، والتي تُساعد في التَّحكم بارتفاع ضغط الدَّم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ما هي دواعي استعمال عقار ديوفان؟</strong></p><p dir="RTL">يُستخدم عقار<strong> </strong>ديوفان لعلاج ارتفاع ضغط الدَّم لدى البالغين والأطفال والمراهقين الذين تتراوح أعمارهم بين 6 إلى 18 عامًا. يُزيد ارتفاع ضغط الدَّم من عبء العمل على القلب والشرايين. إذا استمر ارتفاع ضغط الدَّم لفترة طويلة، فقد يُلحِق ضررًا بالأوعية الدَّموية بالمخ والقلب والكُلى، وقد يُؤدي إلى الإصابة بسكتة دماغية، أو بفشل القلب، أو بالفشل الكُلوي. يُزيد ارتفاع ضغط الدَّم من خطر حدوث النوبات القلبية. إنَّ خفض ضغط دمك ليصل إلى المعدل الطبيعي يقلل من خطر الإصابة بهذه الاضطرابات.</p><p dir="RTL">يُستخدم عقار ديوفان لعلاج المرضى من البالغين المصابين بفشل القلب. يكون فشل القلب مصحوبًا بضيق النفس وتورم القدمين والساقين بسبب تراكم السوائل. يعني فشل القلب أنَّ عضلة القلب لا يمكنها ضخ الدَّم بقوة كافية؛ لتوفير كمية الدَّم اللازمة في جميع أنحاء الجسم.</p><p dir="RTL">يمكن أيضًا استخدام عقار ديوفان لعلاج البالغين بعد التَّعرض لنوبة قلبية (احتشاء عضلة القلب)؛ لتحسين البقاء على قيد الحياة والحد من مشاكل القلب الإضافية.</p><p dir="RTL">يُستخدم عقار ديوفان أيضًا لتأخير تقدم مرض السُّكَّرِي في البالغين الذين يعانون من ارتفاع ضغط الدَّم ومستويات السكر في الدَّم فوق الطبيعية عند الجمع بينه وبين تعديلات نمط الحياة على النحو الموصى به من قبل طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كيفية عمل عقار ديوفان</strong></p><p dir="RTL">الأنجيوتنسين-2 هي مادة طبيعية موجودة في الجسم مهمتها إحداث انقباضٍ بالأوعية الدَّموية، وهو ما يُؤدي إلى ارتفاع ضغط الدَّم لديك. يعمل عقار ديوفان عن طريق إعاقة تأثير الأنجيوتنسين-2. نتيجة لذلك، ترتخي الأوعية الدَّموية وينخفض ضغط الدَّم.</p><p dir="RTL">إذا كانت لديك أية أسئلة حول كيفية عمل عقار ديوفان أو لماذا تم وصف هذا الدَّواء لك، فاستشر طبيبك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>اتبع تعليمات طبيبك بعناية؛ فقد تختلف عن التعليمات &nbsp;العامة الواردة في هذه النَّشرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أ&zwnj;.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; موانع استعمال عقار ديوفان</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من <strong>حساسية</strong> (فرط الحساسية) تجاه فالسارتان أو أيٍّ من المكونات الأخرى بهذا الدَّواء (المدرجة بالقسم 6).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك <strong>مرض شديد بالكبد</strong>.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا <strong>تجاوز حملكِ الشهر الثَّالث</strong> (من الأفضل أيضًا تجنُّب تناول عقار ديوفان في مراحل الحمل المُبكرة - انظري قسم: &quot;الحمل&quot;).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بمرض السُّكَّري أو تُعاني من قصور بوظائف الكُلى ويتم علاجك بدواء خافض لضغط الدَّم يحتوي على أليسكيرين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا انطبق عليك أيٌّ مما سبق، <strong>فأخبر طبيبك ولا تتناول عقار ديوفان.</strong></p><p dir="RTL">ب&zwnj;.&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;الاحتياطات عند استعمال عقار ديوفان</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا كنت تُعاني من</strong> مرض كبدي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بمرض كلوي خطير أو تخضغ للغسيل الكلوي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تُعاني من تضيق بالشريان الكلوي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد خضعت مؤخرًا لجراحة زرع كُلى (حصلت على كُلى جديدة).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مرض شديد بالقلب بخلاف فشل القلب أو النوبة القلبية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد أُصبت من قبل بتورم اللسان والوجه النَّاجم عن تفاعل حساسية يُسمى الوذمة الوعائية عند تناول دواء آخر (بما في ذلك مثبطات الإنْزيم المُحَوِّل للأَنْجيُوتَنْسينِ)، فأخبر طبيبك. إذا حدثت هذه الأعراض عندما تتناول عقار ديوفان، فتوقف عن تناول عقار ديوفان فورًا ولا تتناوله مرة أخرى على الإطلاق. انظر أيضًا قسم: 4، &quot;الأعراض الجانبية المحتملة&quot;.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول الأدوية التي تزيد من كمية البوتاسيوم في الدَّم لديك. تشمل هذه الأدوية مكملات البوتاسيوم أو بدائل الملح التي تحتوي على البوتاسيوم والأدوية المُوَفِّرة للبُوتاسيوم والهيبارين. قد يكون من الضَّروري التَّحقق من كمية البوتاسيوم في الدَّم لديك على فترات منتظمة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من فرط الألدوستيرونية. هذا مرض يصيب الغدد الكظرية؛ حيث إنها تفرز كمية كبيرة جدًّا من هرمون الألدوستيرون. إذا كان ذلك ينطبق عليك، فلا يُوصى باستخدام عقار ديوفان.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا فقدت الكثير من السوائل (الجفاف) بسبب الإسهال أو القيء أو تناوُل جرعات عالية من أقراص الماء (مدرات البول).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول أيًّا من الأدوية التَّالية التي تُستَخدَم لعلاج ارتفاع ضغط الدَّم:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أحد مثبطات الإنْزيم المُحَوِّل للأَنْجيُوتَنْسينِ (على سبيل المثال: إنالابريل، ليزينوبريل، راميبريل)، لا سيما إذا كنت تُعاني من مشاكل بالكُلى متعلقة بمرض السُّكَّري؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أليسكيرين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تُعالَج بأحد مُثبطات إنزيم تحويل الأنجيوتنسين مع بعض الأدوية الأخرى لعلاج فشل القلب لديك، والتي تُعرف باسم مناهضات مستقبلات المينيرالوكورتيكويد (MRA) (على سبيل المثال، سبيرونولاكتون، &nbsp;إبليرينون) أو حاصرات بيتا (على سبيل المثال ميتوبرولول).</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يُجري لك طبيبك فحصًا لوظائف الكُلى وضغط الدَّم وكمية الكهارل (على سبيل المثال: البوتاسيوم) في دمك على فترات منتظمة.</p><p dir="RTL">انظر أيضًا المعلومات تحت عنوان: &quot;لا تتناول عقار ديوفان في الحالات التَّالية&quot;.</p><p dir="RTL">يجب عليكِ إخبار طبيبكِ إذا كنتِ تعتقدين أنكِ حامل (أو قد تصبحين حاملًا). لا يُوصى بتناوُل عقار ديوفان في مراحل الحمل المبكرة، ويجب عدم تناوُله إذا تجاوز حملكِ الشهر الثالث؛ إذ قد يُلْحِق بطفلكِ ضررًا خطيرًا إذا تم استخدامه في هذه المرحلة (انظري قسم: &quot;الحمل&quot;).</p><p dir="RTL">&nbsp;</p><p dir="RTL">ج&zwnj;.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تناول أدوية أخرى أو أعشاب أو مكملات غذائية</p><p dir="RTL"><strong>أخبر طبيبك أو الصيدلي الخاص بك</strong> إذا كنت تتناول أو كنت قد تناولت مؤخرًا أيَّة أدوية أخرى.</p><p dir="RTL">من الممكن أن يتأثر تأثير العلاج إذا تم تناوُل عقار ديوفان مع بعض الأدوية الأخرى. قد يكون من الضَّروري تغيير الجرعة، اتخاذ احتياطات أخرى أو التَّوقف عن تناوُل أحد الأدوية في بعض الحالات. ينطبق ذلك على كلٍّ من الأدوية الوصفية وغير الوصفية، وبشكلٍ خاص:</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>الأدوية الأخرى الخافضة لضغط الدَّم، خاصةً أقراص الماء </strong>(مُدِرات البول)، مُثبطات إنزيم تحويل الأنجيوتنسين (مثل إنالابريل، ليزينوبريل، وما إلى ذلك) أو أليسكيرين (انظر أيضًا معلومات تحت عنوان: &quot;لا تتناول عقار ديوفان في الحالات الآتية&quot; و&quot;تحذيرات واحتياطات&quot;).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>الأدوية التي تزيد من كمية البوتاسيوم </strong>في الدَّم لديك. تشمل هذه الأدوية مكملات البوتاسيوم أو بدائل الملح التي تحتوي على البوتاسيوم والأدوية المُوَفِّرة للبُوتاسيوم والهيبارين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>نوع معين من مسكنات الألم </strong>يُسمى مضادات الالتهاب غير الستيرويدية <strong>(</strong><strong>NSAIDs</strong><strong>).</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض المضادات الحيوية (مجموعة ريفاميسِن)، أو عقار يُستَخدَم لمنع رفض الجسم للعضو المزروع (سيكلوسبورين) أو أحد مضادات فيروسات النسخ العكسي &quot;القهقرية&quot; التي تُستَخدَم لعلاج عدوى فيروس نقص المناعة البشري/ متلازمة نقص المناعة المكتسبة (الإيدز) (ريتونافير). قد تُزيد هذه العقاقير من تأثير عقار ديوفان.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>الليثيوم،</strong> دواء يُستَخدَم لعلاج بعض الأنواع من الأمراض النفسية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>بالإضافة إلى ذلك:</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت <strong>تُعالَج بعد الإصابة بنوبة قلبية، </strong>فلا يوصى بالعلاج المركب <strong>بمُثبطات إنزيم تحويل الأنجيوتنسين </strong>(دواء لعلاج النوبة القلبية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت <strong>تُعالَج من فشل القلب،</strong> فلا يُوصى بالعلاج المركب الثلاثي من <strong>مُثبطات إنزيم تحويل الأنجيوتنسين</strong> <strong>وغيرها من أدوية علاج فشل القلب لديك والتي تُعرف باسم مناهضات مستقبلات المينيرالوكورتيكويد (</strong><strong>MRA</strong><strong>) (على سبيل المثال سبيرونولاكتون، إبليرونون) أو حاصرات بيتا</strong> (على سبيل المثال ميتوبرولول).</p><p dir="RTL">&nbsp;</p><p dir="RTL">د&zwnj;.&nbsp;&nbsp;&nbsp;&nbsp; تناوُل عقار ديوفان مع الطعام والشراب</p><p dir="RTL">يمكنك تناول عقار ديوفان مع الطعام أو بدونه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">كبار السن (بعمر 65 عامًا فأكبر)</p><p dir="RTL">يمكنك أيضًا استخدام عقار ديوفان إذا كنت تبلغ من العمر 65 عامًا أو أكبر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الأطفال (الذين تقل أعمارهم عن 6 أعوام)</p><p dir="RTL">لم يتم التَّثبت من أمان وفعالية عقار ديوفان في الأطفال الذين تقل أعمارهم عن 6 أعوام.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ه&zwnj;.&nbsp;&nbsp;&nbsp; الحمل والرضاعة</p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em><strong>يجب عليكِ إخبار طبيبكِ إذا كنت تعتقدين أنك حامل (<u>أو قد تصبحين حاملًا</u>)</strong> سينصحكِ طبيبكِ عادةً بالتَّوقُّف عن تناوُل عقار ديوفان قبل أن تُصبِحي حاملًا، أَو بِمجرّد أَن تعلمي أنكِ حامل، وسينصحكِ بِتناوُل دواء آخر بدلًا من عقار ديوفان. لا يُوصى باستخدام عقار ديوفان في مراحل الحمل المبكرة، ويجب ألا يتم تناوُله إذا تجاوز حملكِ الشهر الثالث؛ حيث إنه قد يُسبب أضرارًا خطيرة لطفلك إذا تم استخدامه بعد الشهر الثالث من الحمل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>أخبري طبيبك إذا كنتِ مرضعًا، أو إذا كنتِ على وشك البدء في ممارسة الرضاعة.</strong> لا يُوصى باستخدام عقار ديوفان من قِبَل الأمهات المُرضعات، وقد يختار لكِ طبيبك علاجًا آخر إذا كنتِ ترغبين في الإرضاع، خاصةً إذا كان طفلكِ حديث الولادة، أو مبتسرًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">و&zwnj;.&nbsp;&nbsp;&nbsp; تأثير عقار ديوفان على القيادة واستخدام الآلات</p><p dir="RTL">قبل أن تقوم بقيادة مركبة أو استخدام أدوات أو تشغيل آلات أو قبل أن تقوم بأنشطة أخرى تتطلب تركيزًا، تأكَّد من معرفة تأثير عقار فالسارتان عليك. مثله مثل العديد من الأدوية الأخرى التي تُستَخدَم لعلاج ارتفاع ضغط الدَّم، قد يُسبب عقار فالسارتان أحيانًا دوخة وقد يُؤثر على القدرة على التَّركيز.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">اتبع تعليمات طبيبك بعناية؛ لا تتجاوز الجرعة الموصى بها.</p><p dir="RTL">لا يلاحظ المرضى المُصابون بارتفاع ضغط الدَّم غالبًا أي علامات لهذه المشكلة. وكثيرون منهم قد&nbsp; يشعرون أنهم طبيعيون . ولهذا السبب، يُعتبر حفاظك على مواعيدك مع طبيبك غايةً في الأهمية حتى إذا كنت تشعر بأنك على ما يُرام. من المهم جدًّا أن تتناول هذا الدَّواء على النحو الذي يخبرك به طبيبك بالضبط من أجل الحصول على أفضل النتائج وتقليل خطر الآثار الجانبية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">عقار ديوفان معد للتناوُل عن طريق الفم فقط.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ما هي الكمية التي يجب أن تتناولها من عقار ديوفان؟</p><p dir="RTL">تناول هذا الدَّواء على النحو الذي أخبرك به طبيبك بالضبط من أجل الحصول على أفضل النتائج وتقليل خطر الآثار الجانبية. راجع طبيبك أو الصيدلي الخاص بك إذا لم تكن متأكدًا من كيفية الاستخدام. لا يلاحظ الأشخاص المُصابون بارتفاع ضغط الدَّم غالبًا أي علامات لهذه المشكلة. وكثيرون منهم قد&nbsp; يشعرون أنهم طبيعيون . ولهذا السبب، يُعتبر حفاظك على مواعيدك مع طبيبك غايةً في الأهمية حتى إذا كنت تشعر بأنك على ما يُرام.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>المرضى البالغون الذين يعانون من ارتفاع ضغط الدَّم: </strong>الجرعة الموصى بها هي 80 مجم يوميًّا. في بعض الحالات قد يصف طبيبك جرعات أعلى (على سبيل المثال، 160 مجم أو 320 مجم). قد يقوم أيضًا بالجمع بين عقار ديوفان ودواء إضافي (على سبيل المثال، أحد مدرات البول).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون (من عمر 6 إلى 18 عامًا)</strong> <strong>الذين يعانون من ارتفاع ضغط الدَّم:</strong></p><p dir="RTL">في المرضى الذين تكون أوزانهم أقل من 35 كجم، تبلُغ الجرعة الموصى بها 40 مجم من فالسارتان مرَّة واحدة يوميًّا.</p><p dir="RTL">في المرضى الذين تكون أوزانهم 35 كجم أو أكثر، تبلُغ الجرعة الموصى بها 80 مجم من فالسارتان مرَّة واحدة يوميًّا.</p><p dir="RTL">في بعض الحالات، قد يصف طبيبك جرعات أعلى (قد تتم زيادة الجرعة إلى 160 مجم وبحد أقصى إلى 320 مجم).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>المرضى البالغون بعد التَّعرض للإصابة بنوبة قلبية مؤخرًا: </strong>بعد الإصابة بنوبة قلبية، يتم بدء العلاج بصفة عامة في وقت مبكر بعد 12 ساعة، وعادة بجرعة منخفضة تبلغ 20 مجم مرتين يوميًّا. تحصل على جرعة تبلغ 20 مجم عن طريق تقسيم قرص بحجم 40 مجم. سيقوم طبيبك بزيادة هذه الجرعة تدريجيًّا على مدار عدة أسابيع إلى جرعة أقصاها 160 مجم مرتين يوميًّا. تعتمد الجرعة النهائية على ما يمكنك تحمله بصورة فردية كمريض .</p><p dir="RTL">من الممكن إعطاء عقار ديوفان مع علاج آخر للنوبة القلبية، وسيقرر طبيبك العلاج المناسب لك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>المرضى الذين يعانون من فشل القلب:</strong> يبدأ العلاج بشكل عام بجرعة قدرها 40 مجم مرتين يوميًّا. سيقوم طبيبك بزيادة الجرعة تدريجيًّا على مدار عدة أسابيع إلى جرعة بحد أقصى 160 مجم مرتين يوميًّا. تعتمد الجرعة النهائية على ما يمكنك تحمله بصورة فردية كمريض .</p><p dir="RTL">من الممكن إعطاء عقار ديوفان مع علاج آخر لفشل القلب، وسيقرر طبيبك العلاج المناسب لك.</p><p dir="RTL">يمكنك تناول عقار ديوفان مع الطعام أو بدونه. ابتلع قرص عقار ديوفان مع كوب من الماء.</p><p dir="RTL">تناول عقار ديوفان في نفس الوقت من كل يوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أ&zwnj;.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>&nbsp;</strong><strong>الجرعة الزَّائدة من عقار ديوفان</strong></p><p dir="RTL">إذا تعرَّضت لدوخة شديدة و/أو إغماء، فاتصل بطبيبك فورًا واستلقِ. إذا تناوُلت كمية أكبر من اللازم من الأقراص بطريق الخطأ، فاتصل بطبيبك أو الصيدلي الخاص بك أو المستشفى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ب&zwnj;.&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>نسيان تناول جرعة من عقار ديوفان</strong></p><p dir="RTL">إذا أغفلت تناول إحدى الجرعات، فتناولها بمجرد تذكرك لها. مع ذلك، إذا كان موعد الجرعة التَّالية قد اقترب، فتجاوز الجرعة التي أغفلتها.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تتناول جرعة مضاعفة لتعويض جرعة أغفلتها.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ج&zwnj;.&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>التَّوقف عن تناول عقار ديوفان</strong></p><p dir="RTL">قد يُؤدي إيقاف علاجك بعقار ديوفان إلى تفاقم المرض لديك. لا تتوقف عن تناول دوائك ما لم يخبرك طبيبك بذلك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثله مثل كافة الأدوية، قد يُسبب هذا الدَّواء أعراضًا جانبية، على الرَّغم من عدم حدوثها لدى الجميع.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;<strong>بعض الأعراض الجانبية قد تكون خطيرة وتحتاج إلى عناية طبية فورية:</strong></p><p dir="RTL">قد تتعرض للإصابة بأعراض الوذمة الوعائية (تفاعل حساسية محدد)، مثل</p><ul><li dir="RTL">تورُّم الوجه أو الشفتين أو اللسان أو الحلق.</li><li dir="RTL">صعوبة في التَّنفس أو في البلع.</li><li dir="RTL">شرى، حكة.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا أُصِبت بأي من هذه الأعراض، فتوقف عن تناوُل عقار ديوفان واتصل بطبيبك فورًا (انظر أيضًا قسم 2 &quot;تحذيرات واحتياطات&quot;).</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تشمل الأعراض الجانبية الأخرى ما يلي:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>شائعة (قد تُؤثر على ما يصل إلى شخص واحد من كل ١٠&nbsp;أشخاص):</em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوخة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض ضغط الدَّم مع أعراض أو بدون أعراض مثل: الدوخة والإغماء عند الوقوف.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قصور وظائف الكُلى (علامات على قصور وظائف الكُلى).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>غير شائعة (قد تُؤثر على ما يصل إلى شخص واحد من بين كل ١٠٠ شخص):</em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وذمة وعائية (انظر قسم: &quot;بعض الأعراض تحتاج إلى عناية طبية فورية&quot;).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الوعي المفاجئ (غشي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بالدوران (دوار).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قصور شديد في وظائف الكُلى (علامات على الفشل الكُلوي الحاد).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تقلصات عضلية، اضطراب بالنَّظْم القلبي (علامات على فرط بوتاسيوم الدَّم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عُسْرُ التَّنَفُّس، صعوبة التَّنفس عند الاستلقاء، تورم القدمين أو الساقين (علامات على فشل القلب).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سعال.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم بالبطن.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غثيان.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إِسْهال.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعب.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>ضعف.</p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL"><em>غير معروفة (لا يمكن تقدير معدل التكرار من واقع البيانات المتاحة):</em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بثور على الجلد (علامة على الإصابة بالتهاب الجلد الفقاعي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تحدث تفاعلات حساسية مع طفح جلدي وحكة وشرى؛ أعراض الحمى، تورم المفاصل وألم بالمفاصل، ألم بالعضلات، تورُّم العقد الليمفاوية و/ أو أعراض شبيهة بأعراض الأنفلونزا (علامات على داء المصل).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بقع حمراء مائلة إلى اللون الأرجواني، حُمّى، حكة (أعراض التهاب الأوعية الدَّموية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف أو تَكَدُّم غير معتاد (علامات على نقص الصَّفائح الدَّموية).</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>ألم عضلي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمى، التهاب الحلق أو قرح الفم النَّاجمة عن العدوى (أعراض على انخفاض مستوى خلايا الدَّم البيضاء تسمى قلة خلايا العَدِلات).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستوى الهيموجلوبين وانخفاض نسبة خلايا الدَّم الحمراء في الدَّم (مما قد يُؤدي إلى الإصابة بفقر الدَّم في الحالات الشَّديدة).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستوى البوتاسيوم في الدَّم (والذي من الممكن أن يحفز التّقلُّصات العضليّة واضطراب النظم القلبي في الحالات الشَّديدة).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع قيم وظائف الكبد (والتي من الممكن أن تُشير إلى تلف بالكبد) بما في ذلك ارتفاع البيليروبين في الدَّم (مما قد يحفز اصفرار الجلد والعينين في الحالات الشديدة).</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>ارتفاع مستوى نيتروجين يوريا الدَّم وارتفاع مستوى الكرياتينين في الدَّم (وهو ما قد يدل على اضطراب وظائف الكُلى).</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>انخفاض مستوى الصوديوم في الدَّم (وهو ما قد يُؤدي إلى التَّعب، الارتباك، الانتفاض العضلي و/أو التشنجات في الحالات الشديدة).</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يختلف معدل تكرار بعض الآثار الجانبية اعتمادًا على حالتك. على سبيل المثال، لُوحظت آثار جانبية مثل: الدوخة، وقصور وظائف الكُلى، بمعدل أقل تكرارًا في المرضى البالغين الذين عُولجوا من ارتفاع ضغط الدَّم مقارنة بالمرضى البالغين الذين عُولجوا من فشل القلب أو بعد التَّعرض لنوبة قلبية مؤخرًا.</p><p dir="RTL">تكون الآثار الجانبية في الأطفال والمراهقين مماثلة لتلك التي لُوحظت في البالغين.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُحفظ بعيدًا عن مُتناوَل ورؤية الأطفال.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا يُخزَّن في درجة حرارة تتعدى 30 درجة مئوية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تُحفظ الأقراص داخل العبوة الأصلية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا يُستخدم عقار ديوفان بعد انتهاء تاريخ الصلاحية الموضح على العبوة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>تتوافر المادة الفعَّالة </strong>لعقار ديوفان في هيئة أقراص مغلَّفة تحتوي على 40&nbsp;مجم، أو 80&nbsp;مجم، أو 160&nbsp;مجم أو 320&nbsp;مجم فالسارتان.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة في عقار ديوفان هي فالسارتان.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>المكونات الأخرى &nbsp;للأقراص المغلَّفة هي </strong>سليلوز دقيق التَّبلور، كروسبوفيدون، سليكا غروية لا مائية، ستيرات الماغنيسيوم، هيبروميلوز، ثاني أكسيد التيتانيوم (E171)، ماكروجول 8000، أكسيد الحديد الأحمر (E172)، أكسيد الحديد الأصفر (E172)، أكسيد الحديد الأسود (E172) (40 مجم، 160 مجم و 320 مجم)، أكسيد الحديد البني (خليط من أكسيد الحديد الأحمر وأكسيد الحديد الأسود (320 مجم فقط).</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تختلف هذه المعلومات في بعض الدول.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يتوفر عقار ديوفان على هيئة أقراص مغلَّفة بأربعة تركيزات:</p><p dir="RTL">ديوفان 40 مجم أقراص مغلفة صفراء اللون، بيضاوية الشكل وبها خط فاصل محفور على أحد الجانبين، محدبة قليلًا، مشطوفة الحواف، محفور على أحد جانبيها &quot;DO&quot; و &quot;NVR&quot; على الجانب الآخر.خط التَّقسيم الموجود على جانب واحد من عقار ديوفان 40 مجم أقراص مغلفة موجود لتقسيم القرص إلى جرعات متساوية.</p><p dir="RTL">ديوفان 80 مجم أقراص مغلفة ذات لون أحمر شاحب، مستديرة الشَّكل وبها خط فاصل محفور على أحد الجانبين، محدبة قليلًا، مشطوفة الحواف، محفور على أحد جانبيها &quot;D/V &quot; و &quot;NVR&quot; على الجانب الآخر.</p><p dir="RTL">ديوفان 160 مجم أقراص مغلَّفة ذات لون برتقالي يميل إلى الرمادي، بيضاوية، بها خط فاصل محفور على أحد الجانبين، محدبة، محفور على أحد جانبيها &quot;DX/DX&quot; و &quot;NVR&quot; على الجانب الآخر.</p><p dir="RTL">ديوفان 320 مجم أقراص ذات لون بنفسجي مائل إلى الرمادي الداكن، بيضاوية وذات حواف مشطوفة، محفور عليها &quot;DXL&quot; على أحد الجانبين و &quot;NVR&quot; على الجانب الآخر.</p><p dir="RTL">خط التَّقسيم الموجود على جانب واحد من عقار ديوفان 80 مجم، 160 مجم أو 320 مجم أقراص مغلفة موجود فقط لتسهيل كسر القرص من أجل سهولة البلع وليس من أجل التقسيم إلى جرعات متساوية.</p><p dir="RTL">قد لا يتم تسويق جميع العبوات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مالك حق التسويق لهذا المنتج هي شركة نوفارتس فارما إيه جي.</p><p dir="RTL">www.Novartis.com</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            من قبل الوكالة السويدية للمنتجات الطبية في: 03-2018 
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Diovan 40 mg film-coated tablets
Diovan 80 mg film-coated tablets
Diovan 160 mg film-coated tablets
Diovan 320 mg film-coated tablets

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                One tablet contains 40 mg, 80 mg, 160 mg or 320 mg valsartan.
For a full list of excipients, see section 6.1. 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet (FCT)
Valsartan 40 mg: Yellow, ovaloid with bevelled edges, scored on one side; with debossing “DO” on the scored side and “NVR” on the other side. The score line on one side of Valsartan 40 mg FCT is to divide the tablet into equal doses. 
Valsartan 80 mg: Pale red, round with bevelled edges, scored on one side; with debossing “D/V” on the scored side and “NVR” on the other side 
Valsartan 160 mg: Grey-orange, ovaloid, scored on one side; with debossing “DX/DX” on the scored side and “NVR” on the other side
Valsartan 320 mg: Dark grey-violet, ovaloid with bevelled edges with debossing “DXL” on one side and “NVR” on the other side.

The score line on one side of Valsartan 80 mg, 160 mg or 320 mg FCT is only to facilitate breaking for ease of swallowing and not to divide into equal doses.

Appearance of tablets may differ between countries. 
Certain dosage strengths and dosage forms may not be available in all countries.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Hypertension (only 40&nbsp;mg)</u></p><p>Treatment of hypertension in children and adolescents 6 to 18&nbsp;years of age.</p><p>&nbsp;</p><p><u>Hypertension (only 80&nbsp;mg, 160&nbsp;mg and 320&nbsp;mg)</u></p><p>Treatment of essential hypertension in adults, and hypertension in children and adolescents 6 to 18&nbsp;years of age.</p><p>&nbsp;</p><p><u>Recent myocardial infarction (only 40&nbsp;mg, 80&nbsp;mg and 160&nbsp;mg)</u></p><p>Treatment of clinically stable adult patients with symptomatic heart failure or asymptomatic left ventricular systolic dysfunction after a recent (12&nbsp;hours‑10&nbsp;days) myocardial infarction (see sections 4.4 and 5.1).</p><p>&nbsp;</p><p><u>Heart failure (only 40&nbsp;mg, 80&nbsp;mg and 160&nbsp;mg) </u></p><p>Treatment of adult patients with symptomatic heart failure when Angiotensin Converting Enzyme (ACE) inhibitors are not tolerated or in beta-blocker intolerant patients as add-on therapy to ACE inhibitors when mineralocorticoid receptor antagonists cannot be used (see sections 4.2, 4.4, 4.5 and 5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Posology</u></em></p><p>&nbsp;</p><p><u>Hypertension (only 80&nbsp;mg, 160&nbsp;mg and 320&nbsp;mg)</u></p><p>The recommended starting dose of Diovan is 80&nbsp;mg once daily. The antihypertensive effect is substantially present within 2&nbsp;weeks, and maximal effects are attained within 4&nbsp;weeks. In some patients whose blood pressure is not adequately controlled, the dose can be increased to 160&nbsp;mg and to a maximum of 320&nbsp;mg.</p><p>Diovan may also be administered with other antihypertensive agents (see sections 4.3, 4.4, 4.5 and 5.1). The addition of a diuretic such as hydrochlorothiazide will decrease blood pressure even further in these patients.</p><p>&nbsp;</p><p><u>Recent myocardial infarction (only 40&nbsp;mg, 80&nbsp;mg and 160&nbsp;mg)</u></p><p>In clinically stable patients, therapy may be initiated as early as 12&nbsp;hours after a myocardial infarction. After an initial dose of 20&nbsp;mg twice daily, valsartan should be titrated to 40&nbsp;mg, 80&nbsp;mg, and 160&nbsp;mg twice daily over the next few weeks. The starting dose is provided by the 40&nbsp;mg divisible tablet.</p><p>The target maximum dose is 160&nbsp;mg twice daily. In general, it is recommended that patients achieve a dose level of 80&nbsp;mg twice daily by two weeks after treatment initiation and that the target maximum dose, 160&nbsp;mg twice daily, be achieved by three months, based on the patient&#39;s tolerability. If symptomatic hypotension or renal dysfunction occur, consideration should be given to a dose reduction.</p><p>Valsartan may be used in patients treated with other post-myocardial infarction therapies, e.g. thrombolytics, acetylsalicylic acid, beta blockers, statins, and diuretics. The combination with ACE inhibitors is not recommended (see sections 4.4 and 5.1).</p><p>Evaluation of post-myocardial infarction patients should always include assessment of renal function.</p><p>&nbsp;</p><p><u>Heart failure (only 40&nbsp;mg, 80&nbsp;mg and 160&nbsp;mg)</u></p><p>The recommended starting dose of Diovan is 40&nbsp;mg twice daily. Uptitration to 80&nbsp;mg and 160&nbsp;mg twice daily should be done at intervals of at least two weeks to the highest dose, as tolerated by the patient. Consideration should be given to reducing the dose of concomitant diuretics. The maximum daily dose administered in clinical trials is 320&nbsp;mg in divided doses.</p><p>Valsartan may be administered with other heart failure therapies. However, the triple combination of an ACE inhibitor, valsartan and a beta blocker or a potassium-sparing diuretic is not recommended (see sections 4.4 and 5.1). Evaluation of patients with heart failure should always include assessment of renal function.</p><p>&nbsp;</p><p><em><u>Additional information on special populations</u></em></p><p>&nbsp;</p><p><u>Older people</u></p><p>No dose adjustment is required in elderly patients.</p><p>&nbsp;</p><p><u>Patients with Renal impairment</u>No dose adjustment is required for adult patients with a creatinine clearance &gt;10&nbsp;ml/min (see sections 4.4 and 5.2).</p><p><u>Patients with Hepatic impairment</u></p><p>Diovan is contraindicated in patients with severe hepatic impairment, biliary cirrhosis and in patients with cholestasis (see sections 4.3, 4.4 and 5.2). In patients with mild to moderate hepatic impairment without cholestasis, the dose of valsartan should not exceed 80&nbsp;mg.</p><p>&nbsp;</p><p><em><u>Paediatric population</u></em></p><p>&nbsp;</p><p><u>Paediatric hypertension</u></p><p><em>Children and adolescents 6 to 18</em>&nbsp;<em>years of age</em></p><p>The initial dose is 40&nbsp;mg once daily for children weighing below 35&nbsp;kg and 80&nbsp;mg once daily for those weighing 35&nbsp;kg or more. The dose should be adjusted based on blood pressure response. For maximum doses studied in clinical trials please refer to the table below.</p><p>Doses higher than those listed have not been studied and are therefore not recommended.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Weight</strong></p></td><td style="vertical-align:top"><p><strong>Maximum Dose studied in clinical trials</strong></p></td></tr><tr><td style="vertical-align:top"><p>&ge;18 kg to &lt;35 kg</p></td><td style="vertical-align:top"><p>80 mg</p></td></tr><tr><td style="vertical-align:top"><p>&ge; 35 kg to &lt; 80 kg</p></td><td style="vertical-align:top"><p>160 mg</p></td></tr><tr><td style="vertical-align:top"><p>&ge; 80 kg to &le; 160 kg</p></td><td style="vertical-align:top"><p>320 mg</p></td></tr></tbody></table><p>&nbsp;</p></td></tr></tbody></table><p><em>Children less than 6</em>&nbsp;<em>years of age</em></p><p>Available data are described in sections 4.8, 5.1 and 5.2. However safety and efficacy of Diovan in children aged 1 to 6&nbsp;years have not been established.</p><p>&nbsp;</p><p><em><u>Use in paediatric patients aged 6 to 18&nbsp;years with renal impairment</u></em></p><p>Use in paediatric patients with a creatinine clearance &lt;30&nbsp;ml/min and paediatric patients undergoing dialysis has not been studied, therefore valsartan is not recommended in these patients. No dose adjustment is required for paediatric patients with a creatinine clearance &gt;30&nbsp;ml/min. Renal function and serum potassium should be closely monitored (see sections 4.4 and 5.2).</p><p>&nbsp;</p><p><em><u>Use in paediatric patients aged 6 to 18&nbsp;years with hepatic impairment</u></em></p><p>As in adults, Diovan is contraindicated in paediatric patients with severe hepatic impairment, biliary cirrhosis and in patients with cholestasis (see sections 4.3, 4.4 and 5.2). There is limited clinical experience with Diovan in paediatric patients with mild to moderate hepatic impairment. The dose of valsartan should not exceed 80&nbsp;mg in these patients.</p><p>&nbsp;</p><p><em><u>Paediatric heart failure and recent myocardial infarction</u></em></p><p>Diovan is not recommended for the treatment of heart failure or recent myocardial infarction in children and adolescents below the age of 18&nbsp;years due to the lack of data on safety and efficacy.</p><p>&nbsp;</p><p><em><u>Method of administration</u></em></p><p>Diovan may be taken independently of a meal and should be administered with water.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                -	Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
-	Severe hepatic impairment, biliary cirrhosis and cholestasis.
-	Second and third trimester of pregnancy (see sections 4.4 and 4.6).
-	Concomitant use of Diovan with aliskiren-containing products in patients with diabetes mellitus or renal impairment (GFR < 60 mL/min/1.73m2) (see sections 4.5 and 5.1).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Hyperkalaemia</u></p><p>Concomitant use with potassium supplements, potassium-sparing diuretics, salt substitutes containing potassium, or other agents that may increase potassium levels (heparin, etc.) is not recommended. Monitoring of potassium should be undertaken as appropriate.</p><p>&nbsp;</p><p><u>Impaired renal function</u></p><p>There is currently no experience on the safe use in patients with a creatinine clearance &lt;10&nbsp;ml/min and patients undergoing dialysis, therefore valsartan should be used with caution in these patients. No dose adjustment is required for adult patients with creatinine clearance &gt;10&nbsp;ml/min (see sections 4.2 and 5.2).</p><p>&nbsp;</p><p><u>Hepatic impairment</u></p><p>In patients with mild to moderate hepatic impairment without cholestasis, Diovan should be used with caution (see sections 4.2 and 5.2).</p><p>&nbsp;</p><p><u>Sodium- and/or volume-depleted patients</u></p><p>In severely sodium-depleted and/or volume-depleted patients, such as those receiving high doses of diuretics, symptomatic hypotension may occur in rare cases after initiation of therapy with Diovan. Sodium and/or volume depletion should be corrected before starting treatment with Diovan, for example by reducing the diuretic dose.</p><p>&nbsp;</p><p><u>Renal artery stenosis</u></p><p>In patients with bilateral renal artery stenosis or stenosis to a solitary kidney, the safe use of Diovan<em> </em>has not been established.</p><p>Short-term administration of Diovan to twelve patients with renovascular hypertension secondary to unilateral renal artery stenosis did not induce any significant changes in renal haemodynamics, serum creatinine, or blood urea nitrogen (BUN). However, other agents that affect the renin-angiotensin system may increase blood urea and serum creatinine in patients with unilateral renal artery stenosis, therefore monitoring of renal function is recommended when patients are treated with valsartan.</p><p>&nbsp;</p><p><u>Kidney transplantation</u></p><p>There is currently no experience on the safe use of Diovan in patients who have recently undergone kidney transplantation.</p><p><em>&nbsp;</em></p><p><u>Primary hyperaldosteronism</u></p><p>Patients with primary hyperaldosteronism should not be treated with Diovan as their renin-angiotensin system is not activated.</p><p>&nbsp;</p><p><u>Aortic and mitral valve stenosis, obstructive hypertrophic cardiomyopathy</u></p><p>As with all other vasodilators, special caution is indicated in patients suffering from aortic or mitral stenosis, or hypertrophic obstructive cardiomyopathy (HOCM).</p><p>&nbsp;</p><p><u>Pregnancy</u></p><p>Angiotensin II Receptor Antagonists (AIIRAs) should not be initiated during pregnancy. Unless continued AIIRAs therapy is considered essential, patients planning pregnancy should be changed to alternative anti-hypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately, and, if appropriate, alternative therapy should be started (see sections 4.3 and 4.6).</p><p>&nbsp;</p><p><u>Recent myocardial infarction (only 40&nbsp;mg, 80&nbsp;mg and 160&nbsp;mg)</u></p><p>The combination of captopril and valsartan<em> </em>has shown no additional clinical benefit, instead the risk for adverse events increased compared to treatment with the respective therapies (see sections 4.2 and 5.1). Therefore, the combination of valsartan with an ACE inhibitor is not recommended.</p><p>Caution should be observed when initiating therapy in post-myocardial infarction patients. Evaluation of post-myocardial infarction patients should always include assessment of renal function (see section 4.2).</p><p>Use of Diovan in post-myocardial infarction patients commonly results in some reduction in blood pressure, but discontinuation of therapy because of continuing symptomatic hypotension is not usually necessary provided dosing instructions are followed (see section 4.2).</p><p>&nbsp;</p><p><u>Heart Failure (only 40&nbsp;mg, 80&nbsp;mg and 160&nbsp;mg)</u></p><p>The risk of adverse reactions, especially hypotension, hyperkalaemia and decreased renal function (including acute renal failure), may increase when Diovan is used in combination with an ACE inhibitor. In patients with heart failure, the triple combination of an ACE inhibitor, a beta blocker and Diovan has not shown any clinical benefit (see section 5.1). This combination apparently increases the risk for adverse events and is therefore not recommended.&nbsp; Triple combination of an ACE inhibitor, a mineralocorticoid receptor antagonist and valsartan is also not recommended. Use of these combinations should be under specialist supervision and subject to frequent close monitoring of renal function, electrolytes and blood pressure.</p><p>Caution should be observed when initiating therapy in patients with heart failure. Evaluation of patients with heart failure should always include assessment of renal function (see section 4.2).</p><p>Use of Diovan in patients with heart failure commonly results in some reduction in blood pressure, but discontinuation of therapy because of continuing symptomatic hypotension is not usually necessary provided dosing instructions are followed (see section 4.2).</p><p>In patients whose renal function may depend on the activity of the renin-angiotensin-aldosterone system (e.g patients with severe congestive heart failure), treatment with ACE inhibitors has been associated with oliguria and/or progressive azotaemia and in rare cases with acute renal failure and/or death. As valsartan is an angiotensin II receptor blocker, it cannot be excluded that the use of Diovan may be associated with impairment of the renal function.</p><p>ACE inhibitors and angiotensin II receptor blockers should not be used concomitantly in patients with diabetic nephropathy.</p><p><em>&nbsp;</em></p><p><em><u>History of angioedema</u></em></p><p>Angioedema, including swelling of the larynx and glottis, causing airway obstruction and/or swelling of the face, lips, pharynx, and/or tongue has been reported in patients treated with valsartan; some of these patients previously experienced angioedema with other drugs including ACE inhibitors. Diovan should be immediately discontinued in patients who develop angioedema, and Diovan should not be re-administered (see section 4.8).</p><p>&nbsp;</p><p><em><u>Other conditions with stimulation of the renin-angiotensin system (only 320&nbsp;mg)</u></em></p><p>In patients whose renal function may depend on the activity of the renin-angiotensin system (e.g patients with severe congestive heart failure), treatment with angiotensin converting enzyme inhibitors has been associated with oliguria and/or progressive azotaemia and in rare cases with acute renal failure and/or death. As valsartan is an angiotensin II antagonist, it cannot be excluded that the use of Diovan may be associated with impairment of the renal function.</p><p>&nbsp;</p><p><u>Dual Blockade of the Renin-Angiotensin-Aldosterone System (RAAS)</u></p><p>There is evidence that the concomitant use of ACE inhibitors, angiotensin II receptor blockers or aliskiren increases the risk of hypotension, hyperkalaemia, and decreased renal function (including acute renal failure).&nbsp; Dual blockade of the RAAS through the combined use of ACE inhibitors, angiotensin II receptor blockers or aliskiren is therefore not recommended (see sections 4.5 and 5.1).</p><p>If dual blockade therapy is considered absolutely necessary, this should only occur under specialist supervision and subject to frequent close monitoring of renal function, electrolytes and blood pressure. ACE inhibitors and angiotensin II receptor blockers should not be used concomitantly in patients with diabetic nephropathy.</p><p>&nbsp;</p><p><em><u>Paediatric population</u></em></p><p>&nbsp;</p><p><u>Impaired renal function</u></p><p>Use in paediatric patients with a creatinine clearance &lt;30&nbsp;ml/min and paediatric patients undergoing dialysis has not been studied, therefore valsartan is not recommended in these patients. No dose adjustment is required for paediatric patients with a creatinine clearance &gt;30&nbsp;ml/min (see sections 4.2 and 5.2). Renal function and serum potassium should be closely monitored during treatment with valsartan. This applies particularly when valsartan is given in the presence of other conditions (fever, dehydration) likely to impair renal function.</p><p>&nbsp;</p><p><u>Impaired hepatic </u><u>function</u></p><p>As in adults, Diovan is contraindicated in paediatric patients with severe hepatic impairment, biliary cirrhosis and in patients with cholestasis (see sections 4.3 and 5.2). There is limited clinical experience with Diovan in paediatric patients with mild to moderate hepatic impairment. The dose of valsartan should not exceed 80&nbsp;mg in these patients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Dual blockade of the Renin-Angiotensin-</u><u>Aldosterone System (RAAS) with ARBs, ACEIs, or aliskiren</u></p><p>Clinical trial data has shown that dual blockade of the renin-angiotensin-aldosterone-system (RAAS) through the combined use of ACE inhibitors, angiotensin II receptor blockers or aliskiren is associated with a higher frequency of adverse events such as hypotension, hyperkalaemia and decreased renal function (including acute renal failure) compared to the use of a single RAAS-acting agent (see sections 4.3, 4.4 and 5.1).</p><p>&nbsp;</p><p><em><u>Concomitant use not</u></em><em><u> recommended</u></em></p><p>&nbsp;</p><p><em>Lithium</em></p><p>Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with angiotensin converting enzyme inhibitors or angiotensin II receptor antagonists including with Diovan. If the combination proves necessary, a careful monitoring of serum lithium levels is recommended. If a diuretic is also used, the risk of lithium toxicity may presumably be increased further.</p><p><em>Potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium and other substances that may increase potassium levels</em></p><p>If a medicinal product that affects potassium levels is considered necessary in combination with valsartan, monitoring of potassium plasma levels is advised.</p><p>&nbsp;</p><p><em><u>Caution required with concomitant use</u></em></p><p><em>Non-steroidal anti-inflammatory medicines (NSAIDs), including selective COX-2 inhibitors, acetylsalicylic acid &gt;3&nbsp;g/day), and non-selective NSAIDs</em></p><p>When angiotensin II antagonists are administered simultaneously with NSAIDs, attenuation of the antihypertensive effect may occur. Furthermore, concomitant use of angiotensin II antagonists and NSAIDs may lead to an increased risk of worsening of renal function and an increase in serum potassium. Therefore, monitoring of renal function at the beginning of the treatment is recommended, as well as adequate hydration of the patient.</p><p>&nbsp;</p><p><em><u>Transporters</u></em><br />In vitro data indicates that valsartan is a substrate of the hepatic uptake transporter OATP1B1/OATP1B3 and the hepatic efflux transporter MRP2. The clinical relevance of this finding is unknown. Co-administration of inhibitors of the uptake transporter (eg. rifampin, ciclosporin) or efflux transporter (eg. ritonavir) may increase the systemic exposure to valsartan. Exercise appropriate care when initiating or ending concomitant treatment with such drugs.</p><p>&nbsp;</p><p><em>Others</em></p><p>In drug interaction studies with valsartan, no interactions of clinical significance have been found with valsartan or any of the following substances: cimetidine, warfarin, furosemide, digoxin, atenolol, indometacin, hydrochlorothiazide, amlodipine, glibenclamide.</p><p>&nbsp;</p><p><em><u>Paediatric population</u></em></p><p>In hypertension in children and adolescents, where underlying renal abnormalities are common, caution is recommended with the concomitant use of valsartan and other substances that inhibit the renin angiotensin aldosterone system which may increase serum potassium. Renal function and serum potassium should be closely monitored.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Pregnancy</u></em></p><p>&nbsp;</p><p>The use of Angiotensin II Receptor Antagonists (AIIRAs) is not recommended during the first trimester of pregnancy (see section 4.4). The use of AIIRAs is contra-indicated during the second and third trimester of pregnancy (see sections 4.3 and 4.4).</p><p>Epidemiological evidence regarding the risk of teratogenicity following exposure to ACE inhibitors during the first trimester of pregnancy has not been conclusive; however, a small increase in risk cannot be excluded. Whilst there is no controlled epidemiological data on the risk with AIIRAs, similar risks may exist for this class of drugs. Unless continued AIIRA therapy is considered essential, patients planning pregnancy should be changed to alternative anti-hypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately, and, if appropriate, alternative therapy should be started.</p><p>AIIRAs therapy exposure during the second and third trimesters is known to induce human fetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalaemia); see also section 5.3 &ldquo;Preclinical safety data&rdquo;.</p><p>Should exposure to AIIRAs have occurred from the second trimester of pregnancy, ultrasound check of renal function and skull is recommended.</p><p>Infants whose mothers have taken AIIRAs should be closely observed for hypotension (see also sections 4.3 and 4.4).</p><p>&nbsp;</p><p><em><u>Breast-feeding</u></em></p><p>Because no information is available regarding the use of valsartan during breastfeeding, Diovan is not recommended and alternative treatments with better established safety profiles during breast-feeding are preferable, especially while nursing a newborn or preterm infant.</p><p>&nbsp;</p><p><em><u>Fertility</u></em></p><p>Valsartan had no adverse effects on the reproductive performance of male or female rats at oral doses up to 200&nbsp;mg/kg/day. This dose is 6&nbsp;times the maximum recommended human dose on a mg/m<sup>2</sup> basis (calculations assume an oral dose of 320&nbsp;mg/day and a 60-kg patient).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive have been performed. When driving vehicles or operating machines it should be taken into account that occasionally dizziness or weariness may occur.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In controlled clinical studies in adult patients with hypertension, the overall incidence of adverse drug reactions (ADRs) was comparable with placebo and is consistent with the pharmacology of valsartan. The incidence of ADRs did not appear to be related to dose or treatment duration and also showed no association with gender, age or race.</p><p>The ADRs reported from clinical studies, post-marketing experience and laboratory findings are listed below according to system organ class.</p><p>&nbsp;</p><p><strong><u>Adverse</u></strong><strong><u> Drug Reactions</u></strong></p><p>Adverse drug reactions are ranked by frequency, the most frequent first, using the following convention: very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000) very rare (&lt;1/10,000), not known (frequency cannot be estimated from the available data).</p><p>Within each frequency grouping, adverse drug reactions are ranked in order of decreasing seriousness.</p><p>For all the ADRs reported from post-marketing experience and laboratory findings, it is not possible to apply any ADR frequency and therefore they are mentioned with a &quot;not known&quot; frequency</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><caption>Table 1&nbsp; : Adverse drug reactions in Hypertension</caption><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Hemoglobin decreased, hematocrit decreased, <sup>&nbsp;</sup>neutropenia, thrombocytopenia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Hypersensitivity including serum sickness</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Blood potassium increased , hyponatraemia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Ear and labyrinth system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Vertigo</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Vasculitis</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Cough</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Abdominal pain</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Hepato-biliary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Liver function test abnormal including blood bilirubin increase</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Angioedema, dermatitis bullous, rash, pruritus</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Myalgia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Renal failure and impairment,<sup> </sup>blood creatinine increased</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Fatigue</p></td></tr></tbody></table><p>&nbsp;</p><p>Pediatric population (Hypertension)</p><p><u>Hypertension</u></p><p>The antihypertensive effect of valsartan has been evaluated in two randomised, double-blind clinical studies in 561&nbsp;paediatric patients from 6 to 18&nbsp;years of age. With the exception of isolated gastrointestinal disorders (like abdominal pain, nausea, vomiting) and dizziness, no relevant differences in terms of type, frequency and severity of adverse reactions were identified between the safety profile for paediatric patients aged 6 to 18&nbsp;years and that previously reported for adult patients.</p><p>Neurocognitive and developmental assessment of paediatric patients aged 6&nbsp;to 16&nbsp;years of age revealed no overall clinically relevant adverse impact after treatment with Diovan for up to one year.</p><p>In a double-blind randomized study in 90&nbsp;children aged 1 to 6&nbsp;years, which was followed by a one-year open-label extension, two deaths and isolated cases of marked liver transaminases elevations were observed. These cases occurred in a population who had significant comorbidities. A causal relationship to Diovan has not been established. In a second study in which 75&nbsp;children aged 1 to 6&nbsp;years were randomised, no significant liver transaminase elevations or death occurred with valsartan treatment.</p><p>Hyperkalaemia was more frequently observed in children and adolescents aged 6 to 18&nbsp;years with underlying chronic kidney disease.</p><p>The safety profile seen in controlled-clinical studies in adult patients with post-myocardial infarction and/or heart failure varies from the overall safety profile seen in hypertensive patients. This may relate to the patients underlying disease. ADRs that occurred in adult patients with post-myocardial infarction and/or heart failure patients are listed below.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Post-myocardial infarction and/or heart failure (studied in adult patients only)</u></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><caption>Table 2 :&nbsp;&nbsp;Adverse drug reactions in heart failure and/or post-myocardial infarction</caption><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Thrombocytopenia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Hypersensitivity including serum sickness</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Hyperkalaemia<sup>#</sup></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Increase of serum potassium, hyponatraemia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Dizziness,<sup> </sup>postural dizziness</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Syncope, headache</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Ear and labyrinth system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Vertigo</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Cardiac failure</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Hypotension, orthostatic hypotension</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Vasculitis</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Cough</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Nausea, diarrhea</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Hepato-biliary disorders </strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Elevation of liver function values</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Angioedema</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>, rash, pruritus</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Myalgia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Renal failure and impairment</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Acute renal failure, blood creatinine<sup> </sup>increased</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Blood Urea increased</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Asthenia, fatigue</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>To report any side effect(s):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Saudi Arabia</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Saudi Food and Drug Authority National Pharmacovigilance Center (NPC):</p><p>o Fax: +966112057662</p><p>o Call NPC at +966-11-2038222, Exts: 2317-2356-2340.</p><p>o Toll free phone: 8002490000</p><p>o SFDA call center: 19999</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: https://ade.sfda.gov.sa</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patient Safety Department Novartis Consulting AG - Saudi Arabia:</p><p>o Toll Free Number: 8001240078</p><p>o Phone: +996112658100</p><p>o Fax: +966112658107</p><p>o Email: adverse.events@novartis.com</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp; Other GCC States:</p><p>-&nbsp; Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Symptoms</u></p><p>Overdose with Diovan may result in marked hypotension, which could lead to depressed level of consciousness, circulatory collapse and/or shock.</p><p>&nbsp;</p><p><u>Treatment</u></p><p>The therapeutic measures depend on the time of ingestion and the type and severity of the symptoms; stabilisation of the circulatory condition is of prime importance.</p><p>If hypotension occurs, the patient should be placed in a supine position and blood volume correction should be undertaken.</p><p>Valsartan is unlikely to be removed by haemodialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Angiotensin II Antagonists, plain, ATC code: C09CA03</p><p>Valsartan is an orally active, potent, and specific angiotensin II (Ang II) receptor antagonist. It acts selectively on the AT<sub>1</sub> receptor subtype, which is responsible for the known actions of angiotensin II. The increased plasma levels of Ang II following AT<sub>1</sub> receptor blockade with valsartan may stimulate the unblocked AT<sub>2</sub> receptor, which appears to counterbalance the effect of the AT<sub>1</sub> receptor. Valsartan does not exhibit any partial agonist activity at the AT<sub>1</sub> receptor and has much (about 20,000&nbsp;fold) greater affinity for the AT<sub>1</sub> receptor than for the AT<sub>2</sub> receptor. Valsartan is not known to bind to or block other hormone receptors or ion channels known to be important in cardiovascular regulation.</p><p>Valsartan does not inhibit ACE (also known as kininase II) which converts Ang I to Ang II and degrades bradykinin. Since there is no effect on ACE and no potentiation of bradykinin or substance P, angiotensin II antagonists are unlikely to be associated with coughing. In clinical trials where valsartan was compared with an ACE inhibitor, the incidence of dry cough was significantly (p&lt;0.05) less in patients treated with valsartan than in those treated with an ACE inhibitor (2.6% versus 7.9% respectively). In a clinical trial of patients with a history of dry cough during ACE inhibitor therapy, 19.5% of trial subjects receiving valsartan and 19.0% of those receiving a thiazide diuretic experienced cough compared to 68.5% of those treated with an ACE inhibitor (p&lt;0.05).</p><p>&nbsp;</p><p><u>Hypertension (only 80&nbsp;mg, 160&nbsp;mg and 320&nbsp;mg)</u></p><p>Administration of Diovan to patients with hypertension results in reduction of blood pressure without affecting pulse rate.</p><p>In most patients, after administration of a single oral dose, onset of antihypertensive activity occurs within 2&nbsp;hours, and the peak reduction of blood pressure is achieved within 4‑6&nbsp;hours. The antihypertensive effect persists over 24&nbsp;hours after dosing. During repeated dosing, the antihypertensive effect is substantially present within 2&nbsp;weeks, and maximal effects are attained within 4&nbsp;weeks and persist during long-term therapy. Combined with hydrochlorothiazide, a significant additional reduction in blood pressure is achieved.</p><p>Abrupt withdrawal of Diovan has not been associated with rebound hypertension or other adverse clinical events.</p><p>In hypertensive patients with type&nbsp;2 diabetes and microalbuminuria, valsartan has been shown to reduce the urinary excretion of albumin. The MARVAL (Micro Albuminuria Reduction with Valsartan) study assessed the reduction in urinary albumin excretion (UAE) with valsartan (80‑160&nbsp;mg/od) versus amlodipine (5‑10&nbsp;mg/od), in 332 type&nbsp;2 diabetic patients (mean age: 58&nbsp;years; 265&nbsp;men) with microalbuminuria (valsartan: 58&nbsp;&micro;g/min; amlodipine: 55.4&nbsp;&micro;g/min), normal or high blood pressure and with preserved renal function (blood creatinine &lt;120&nbsp;&micro;mol/l). At 24&nbsp;weeks, UAE was reduced (p&lt;0.001) by 42% (&ndash;24.2&nbsp;&micro;g/min; 95% CI: &ndash;40.4 to &ndash;19.1) with valsartan and approximately 3% (&ndash;1.7&nbsp;&micro;g/min; 95% CI: &ndash;5.6 to 14.9) with amlodipine despite similar rates of blood pressure reduction in both groups.</p><p>The Diovan Reduction of Proteinuria (DROP) study further examined the efficacy of valsartan in reducing UAE in 391 hypertensive patients (BP=150/88&nbsp;mmHg) with type&nbsp;2 diabetes, albuminuria (mean=102&nbsp;&micro;g/min; 20‑700&nbsp;&micro;g/min) and preserved renal function (mean serum creatinine = 80&nbsp;&micro;mol/l). Patients were randomized to one of 3&nbsp;doses of valsartan (160, 320 and 640&nbsp;mg/od) and treated for 30&nbsp;weeks. The purpose of the study was to determine the optimal dose of valsartan for reducing UAE in hypertensive patients with type&nbsp;2 diabetes. At 30&nbsp;weeks, the percentage change in UAE was significantly reduced by 36% from baseline with valsartan 160&nbsp;mg (95%CI: 22 to 47%), and by 44% with valsartan 320&nbsp;mg (95%CI: 31 to 54%). It was concluded that 160‑320&nbsp;mg of valsartan produced clinically relevant reductions in UAE in hypertensive patients with type&nbsp;2 diabetes.</p><p>&nbsp;</p><p><u>Recent myocardial infarction (only 40&nbsp;mg, 80&nbsp;mg and 160&nbsp;mg)</u></p><p>The VALsartan In Acute myocardial iNfarcTion trial (VALIANT) was a randomised, controlled, multinational, double-blind study in 14,703&nbsp;patients with acute myocardial infarction and signs, symptoms or radiological evidence of congestive heart failure and/or evidence of left ventricular systolic dysfunction (manifested as an ejection fraction &le;40% by radionuclide ventriculography or &le;35% by echocardiography or ventricular contrast angiography). Patients were randomised within 12&nbsp;hours to 10&nbsp;days after the onset of myocardial infarction symptoms to valsartan, captopril, or the combination of both. The mean treatment duration was two years. The primary endpoint was time to all-cause mortality.</p><p>Valsartan was as effective as captopril in reducing all-cause mortality after myocardial infarction. All-cause mortality was similar in the valsartan (19.9%), captopril (19.5%), and valsartan + captopril (19.3%) groups. Combining valsartan with captopril did not add further benefit over captopril alone. There was no difference between valsartan and captopril in all-cause mortality based on age, gender, race, baseline therapies or underlying disease. Valsartan was also effective in prolonging the time to and reducing cardiovascular mortality, hospitalisation for heart failure, recurrent myocardial infarction, resuscitated cardiac arrest, and non-fatal stroke (secondary composite endpoint).</p><p>The safety profile of valsartan was consistent with the clinical course of patients treated in the post-myocardial infarction setting. Regarding renal function, doubling of serum creatinine was observed in 4.2% of valsartan-treated patients, 4.8% of valsartan+captopril-treated patients, and 3.4% of captopril-treated patients. Discontinuations due to various types of renal dysfunction occurred in 1.1% of valsartan-treated patients, 1.3% in valsartan+captopril patients, and 0.8% of captopril patients. An assessment of renal function should be included in the evaluation of patients post-myocardial infarction.</p><p>There was no difference in all-cause mortality, cardiovascular mortality or morbidity when beta blockers were administered together with the combination of valsartan + captopril, valsartan alone, or captopril alone. Irrespective of treatment, mortality was lower in the group of patients treated with a beta blocker, suggesting that the known beta blocker benefit in this population was maintained in this trial.</p><p>&nbsp;</p><p><u>Heart failure (only 40&nbsp;mg, 80&nbsp;mg and 160&nbsp;mg)</u></p><p>Val-HeFT was a randomised, controlled, multinational clinical trial of valsartan compared with placebo on morbidity and mortality in 5,010 NYHA class II (62%), III (36%) and IV (2%) heart failure patients receiving usual therapy with LVEF &lt;40% and left ventricular internal diastolic diameter (LVIDD) &gt;2.9&nbsp;cm/m<sup>2</sup>. Baseline therapy included ACE inhibitors (93%), diuretics (86%), digoxin (67%) and beta blockers (36%). The mean duration of follow-up was nearly two years. The mean daily dose of Diovan in Val-HeFT was 254&nbsp;mg. The study had two primary endpoints: all cause mortality (time to death) and composite mortality and heart failure morbidity (time to first morbid event) defined as death, sudden death with resuscitation, hospitalisation for heart failure, or administration of intravenous inotropic or vasodilator agents for four hours or more without hospitalisation.</p><p>All cause mortality was similar (p=NS) in the valsartan (19.7%) and placebo (19.4%) groups. The primary benefit was a 27.5% (95% CI: 17 to 37%) reduction in risk for time to first heart failure hospitalisation (13.9% vs. 18.5%). Results appearing to favour placebo (composite mortality and morbidity was 21.9% in placebo vs. 25.4% in valsartan group) were observed for those patients receiving the triple combination of an ACE inhibitor, a beta blocker and valsartan.</p><p>In a subgroup of patients not receiving an ACE inhibitor (n=366), the morbidity benefits were greatest. In this subgroup all-cause mortality was significantly reduced with valsartan compared to placebo by 33% (95% CI: &ndash;6% to 58%) (17.3% valsartan vs. 27.1% placebo) and the composite mortality and morbidity risk was significantly reduced by 44% (24.9% valsartan vs. 42.5% placebo).</p><p>In patients receiving an ACE inhibitor without a beta-blocker, all cause mortality was similar (p=NS) in the valsartan (21.8%) and placebo (22.5%) groups. Composite mortality and morbidity risk was significantly reduced by 18.3% (95% CI: 8% to 28%) with valsartan compared with placebo (31.0% vs. 36.3%).</p><p>In the overall Val-HeFT population, valsartan treated patients showed significant improvement in NYHA class, and heart failure signs and symptoms, including dyspnoea, fatigue, oedema and rales compared to placebo. Patients treated with valsartan had a better quality of life as demonstrated by change in the Minnesota Living with Heart Failure Quality of Life score from baseline at endpoint than placebo. Ejection fraction in valsartan treated patients was significantly increased and LVIDD significantly reduced from baseline at endpoint compared to placebo.</p><p>&nbsp;</p><p><u>Other: dual blockade of the renin-angiotensin-aldosterone system (RAAS)</u></p><p>Two large randomised, controlled trials (ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) and VA NEPHRON-D (The Veterans Affairs Nephropathy in Diabetes)) have examined the use of the combination of an ACE-inhibitor with an angiotensin II receptor blocker.</p><p>ONTARGET was a study conducted in patients with a history of cardiovascular or cerebrovascular disease, or type 2 diabetes mellitus accompanied by evidence of end-organ damage. VA NEPHRON-D was a study in patients with type 2 diabetes mellitus and diabetic nephropathy. These studies have shown no significant beneficial effect on renal and/or cardiovascular outcomes and mortality, while an increased risk of hyperkalaemia, acute kidney injury and/or hypotension as compared to monotherapy was observed. Given their similar pharmacodynamic properties, these results are also relevant for other ACE inhibitors and angiotensin II receptor blockers. ACE inhibitors and angiotensin II receptor blockers should therefore not be used concomitantly in patients with diabetic nephropathy.</p><p>ALTITUDE (Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints) was a study designed to test the benefit of adding aliskiren to a standard therapy of an ACE inhibitor or an angiotensin II receptor blocker in patients with type 2 diabetes mellitus and chronic kidney disease, cardiovascular disease, or both. The study was terminated early because of an increased risk of adverse outcomes. Cardiovascular death and stroke were both numerically more frequent in the aliskiren group than in the placebo group and adverse events and serious adverse events of interest (hyperkalaemia, hypotension and renal dysfunction) were more frequently reported in the aliskiren group than in the placebo group.</p><p>&nbsp;</p><p><em><u>Paediatric population</u></em></p><p>&nbsp;</p><p><u>Hypertension</u></p><p>The antihypertensive effect of valsartan have been evaluated in four randomized, double-blind clinical studies in 561&nbsp;paediatric patients from 6 to 18&nbsp;years of age and 165&nbsp;paediatric patients 1 to 6&nbsp;years of age. Renal and urinary disorders, and obesity were the most common underlying medical conditions potentially contributing to hypertension in the children enrolled in these studies.</p><p>&nbsp;</p><p><em><u>Clinical experience in children at or above 6</u></em><u>&nbsp;<em>years of age</em></u></p><p>In a clinical study involving 261&nbsp;hypertensive paediatric patients 6&nbsp;to 16&nbsp;years of age, patients who weighed &lt;35&nbsp;kg received 10, 40 or 80&nbsp;mg of valsartan tablets daily (low, medium and high doses), and patients who weighed &ge;35&nbsp;kg received 20, 80, and 160&nbsp;mg of valsartan tablets daily (low, medium and high doses). At the end of 2&nbsp;weeks, valsartan reduced both systolic and diastolic blood pressure in a dose-dependent manner. Overall, the three dose levels of valsartan (low, medium and high) significantly reduced systolic blood pressure by 8, 10, 12&nbsp;mm&nbsp;Hg from the baseline, respectively. Patients were re-randomized to either continue receiving the same dose of valsartan or were switched to placebo. In patients who continued to receive the medium and high doses of valsartan, systolic blood pressure at trough was -4&nbsp;and -7&nbsp;mm&nbsp;Hg lower than patients who received the placebo treatment. In patients receiving the low dose of valsartan, systolic blood pressure at trough was similar to that of patients who received the placebo treatment. Overall, the dose-dependent antihypertensive effect of valsartan was consistent across all the demographic subgroups.</p><p>In another clinical study involving 300&nbsp;hypertensive paediatric patients 6&nbsp;to 18&nbsp;years of age, eligible patients were randomized to receive valsartan or enalapril tablets for 12&nbsp;weeks. Children weighing between &ge;18&nbsp;kg and &lt;35&nbsp;kg received valsartan 80&nbsp;mg or enalapril 10&nbsp;mg; those between &ge;35&nbsp;kg and &lt;80&nbsp;kg received valsartan 160&nbsp;mg or enalapril 20&nbsp;mg; those &ge;80&nbsp;kg received valsartan 320&nbsp;mg or enalapril 40&nbsp;mg. Reductions in systolic blood pressure were comparable in patients receiving valsartan (15&nbsp;mmHg) and enalapril (14&nbsp;mm&nbsp;Hg) (non-inferiority p-value &lt;0.0001). Consistent results were observed for diastolic blood pressure with reductions of 9.1&nbsp;mmHg and 8.5&nbsp;mmHg with valsartan and enalapril, respectively.</p><p>&nbsp;</p><p><em><u>Clinical experience in children less than 6</u></em><u>&nbsp;<em>years of age</em></u></p><p>Two clinical studies were conducted in patients aged 1 to 6&nbsp;years with 90&nbsp;and 75&nbsp;patients, respectively. No children below the age of 1&nbsp;year were enrolled in these studies. In the first study, the efficacy of valsartan was confirmed compared to placebo but a dose-response could not be demonstrated. In the second study, higher doses of valsartan were associated with greater BP reductions, but the dose response trend did not achieve statistical significance and the treatment difference compared to placebo was not significant. Because of these inconsistencies, valsartan is not recommended in this age group (see section 4.8).</p><p>The European Medicines Agency has waived the obligation to submit the results of studies with Diovan in all subsets of the paediatric population in heart failure and heart failure after recent myocardial infarction. See section 4.2 for information on paediatric use.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Absorption</strong></p><p>Following oral administration of valsartan alone, peak plasma concentrations of valsartan are reached in 2&ndash;4&nbsp;hours with tablets and 1&ndash;2&nbsp;hours with solution formulation. Mean absolute bioavailability is 23% and 39% with tablets and solution formulation, respectively. Food decreases exposure (as measured by AUC) to valsartan by about 40% and peak plasma concentration (C<sub>max</sub>) by about 50%, although from about 8&nbsp;h post dosing plasma valsartan concentrations are similar for the fed and fasted groups. This reduction in AUC is not, however, accompanied by a clinically significant reduction in the therapeutic effect, and valsartan can therefore be given either with or without food.</p><p><strong>Distribution</strong></p><p>Steady-state volume of distribution of valsartan after intravenous administration is about 17&nbsp;liters, indicating that valsartan is not distributed into tissues extensively. Valsartan is highly bound to serum proteins (94&ndash;97%), mainly serum albumin.</p><p><strong>Biotransformation</strong></p><p>Valsartan is not biotransformed to a high extent as only about 20% of dose is recovered as metabolites. A hydroxy metabolite has been identified in plasma at low concentrations (less than 10% of the valsartan AUC). This metabolite is pharmacologically inactive.</p><p><strong>Elimination</strong></p><p>Valsartan shows multiexponential decay kinetics (t&frac12;&alpha; &lt;1 h and t&frac12;&szlig; about 9 h). Valsartan is primarily eliminated in feces (about 83% of dose) and urine (about 13% of dose), mainly as unchanged drug. Following intravenous administration, plasma clearance of valsartan is about 2 L/h and its renal clearance is 0.62 L/h (about 30% of total clearance). The half-life of valsartan is 6 hours.</p><p>&nbsp;</p><p><u>In heart failure patients</u><u> (only 40&nbsp;mg, 80&nbsp;mg and 160&nbsp;mg):</u></p><p>The average time to peak concentration and elimination half-life of valsartan in heart failure patients are similar to that observed in healthy volunteers. AUC and C<sub>max</sub> values of valsartan are almost proportional with increasing dose over the clinical dosing range (40 to 160&nbsp;mg twice a day). The average accumulation factor is about 1.7. The apparent clearance of valsartan following oral administration is approximately 4.5&nbsp;l/h. Age does not affect the apparent clearance in heart failure patients.</p><p>&nbsp;</p><p>&nbsp;</p><p>Special populations</p><p><strong>Geriatric patients (aged 65 years or above)</strong></p><p>A somewhat higher systemic exposure to valsartan was observed in some elderly subjects compared to young subjects; however, this has not been shown to have any clinical significance.</p><p>Impaired renal function</p><p>As expected for a compound where renal clearance accounts for only 30% of total plasma clearance, no correlation was seen between renal function and systemic exposure to valsartan. Dose adjustment is therefore not required in patients with renal impairment (creatinine clearance &gt;10&nbsp;ml/min). There is currently no experience on the safe use in patients with a creatinine clearance &lt;10&nbsp;ml/min and patients undergoing dialysis, therefore valsartan should be used with caution in these patients (see sections 4.2 and 4.4).</p><p>&nbsp;</p><p><strong><u>Hepatic impairment</u></strong></p><p>About 70% of the absorbed dose is excreted in the bile mainly as unchanged compound. Valsartan does not undergo extensive biotransformation, and, as expected, systemic exposure to valsartan is not correlated with the degree of liver dysfunction. No dose adjustment for valsartan is therefore necessary in patients with hepatic insufficiency of non-biliary origin and without cholestasis. The AUC with valsartan has been observed to approximately double in patients with biliary cirrhosis or biliary obstruction (see section 4.4).</p><p>Pediatric population</p><p>In a study of 26&nbsp;pediatric hypertensive patients (aged 1 to 16&nbsp;years) given a single dose of a suspension of valsartan (mean: 0.9&nbsp;to 2&nbsp;mg/kg, with a maximum dose of 80&nbsp;mg), the clearance (liters/h/kg) of valsartan was comparable across the age range of 1 to 16&nbsp;years and similar to that of adults receiving the same formulation (see section 4.4 in pediatric patients).</p><p><strong>&nbsp;</strong></p><p><u>Impaired renal function</u></p><p>Use in paediatric patients with a creatinine clearance &lt;30&nbsp;ml/min and paediatric patients undergoing dialysis has not been studied, therefore valsartan is not recommended in these patients. No dose adjustment is required for paediatric patients with a creatinine clearance &gt;30&nbsp;ml/min. Renal function and serum potassium should be closely monitored (see sections 4.2 and 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential.</p><p>In rats, maternally toxic doses (600&nbsp;mg/kg/day) during the last days of gestation and lactation led to lower survival, lower weight gain and delayed development (pinna detachment and ear-canal opening) in the offspring (see section 4.6). These doses in rats (600&nbsp;mg/kg/day) are approximately 18&nbsp;times the maximum recommended human dose on a mg/m<sup>2</sup> basis (calculations assume an oral dose of 320&nbsp;mg/day and a 60-kg patient).</p><p>In non-clinical safety studies, high doses of valsartan (200 to 600&nbsp;mg/kg body weight) caused in rats a reduction of red blood cell parameters (erythrocytes, haemoglobin, haematocrit) and evidence of changes in renal haemodynamics (slightly raised plasma urea, and renal tubular hyperplasia and basophilia in males). These doses in rats (200 and 600&nbsp;mg/kg/day) are approximately 6 and 18&nbsp;times the maximum recommended human dose on a mg/m<sup>2</sup> basis (calculations assume an oral dose of 320&nbsp;mg/day and a 60-kg patient).</p><p>In marmosets at similar doses, the changes were similar though more severe, particularly in the kidney where the changes developed to a nephropathy which included raised urea and creatinine.</p><p>Hypertrophy of the renal juxtaglomerular cells was also seen in both species. All changes were considered to be caused by the pharmacological action of valsartan which produces prolonged hypotension, particularly in marmosets. For therapeutic doses of valsartan in humans, the hypertrophy of the renal juxtaglomerular cells does not seem to have any relevance.</p><p>&nbsp;</p><p><em><u>Paediatric population</u></em></p><p>Daily oral dosing of neonatal/juvenile rats (from a postnatal day 7&nbsp;to postnatal day&nbsp;70) with valsartan at doses as low as 1&nbsp;mg/kg/day (about 10‑35% of the maximum recommended paediatric dose of 4&nbsp;mg/kg/day on systemic exposure basis) produced persistent, irreversible kidney damage. These effects above mentioned represent an expected exaggerated pharmacological effect of angiotensin converting enzyme inhibitors and angiotensin II type 1&nbsp;blockers; such effects are observed if rats are treated during the first 13&nbsp;days of life. This period coincides with 36&nbsp;weeks of gestation in humans, which could occasionally extend up to 44&nbsp;weeks after conception in humans. The rats in the juvenile valsartan study were dosed up to day&nbsp;70, and effects on renal maturation (postnatal 4‑6&nbsp;weeks) cannot be excluded. Functional renal maturation is an ongoing process within the first year of life in humans. Consequently, a clinical relevance in children &lt;1&nbsp;year of age cannot be excluded, while preclinical data do not indicate a safety concern for children older than 1&nbsp;year.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Tablets:</strong> microcrystalline cellulose, crospovidone, colloidal anhydrous silica, magnesium stearate, hypromellose, titanium dioxide (E171), macrogol 8000, red iron oxide (E172), yellow iron oxide (E172), black iron oxide (E172; 40&nbsp;mg, 160&nbsp;mg and 320&nbsp;mg tablets only), brown iron oxide (mixture of red iron oxide and black iron oxide (320&nbsp;mg tablets only).</p><p>Pharmaceutical formulations may vary between countries.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not Store above 30&deg;C.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diovan should not be used after the date marked &ldquo;EXP&rdquo; on the pack.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diovan must be kept out of the reach and sight of children.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store in the original package.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Protect from moisture.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>PVC/PE/PVDC/Alu or PVC/PVDC/Alu blisters</p><p>Pack sizes: 7, 14, 28, 30, 56, 90, 98 film-coated tablets</p><p>&nbsp;</p><p>PVC/PE/PVDC/Alu or PVC/PVDC/Alu calendar blisters</p><p>Pack sizes: 14, 28, 56, 98, 280 film-coated tablets</p><p>&nbsp;</p><p>PVC/PE/PVDC/Alu or PVC/PVDC/Alu perforated unit dose blisters</p><p>Pack sizes: 56x1, 98x1, 280x1 film-coated tablets</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The Marketing Authorization Holder for this Product is Novartis Pharma AG. 
www.Novartis.com 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                04 / 2015 by Swedish Medical Products Agency
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>